Rapport Therapeutics, Inc.

RAPP

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors Perceptive Advisors

AI Signal

## Signal Note: Baker Bros.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 1,547,090Value: $46.9M

## Signal Note: Baker Bros. Initiates Large Position in Rapport Therapeutics (RAPP) Baker Bros. Advisors has taken a significant new position in Rapport Therapeutics, a clinical-stage company developing subtype-selective GABAA receptor modulators, with lead asset RAP-219 targeting focal epilepsy. **Note: The reported position value (~$47B) appears to be a data error—likely ~$46.9M based on share count and recent trading prices, which would still represent a meaningful conviction bet for a concentrated, specialist fund.** Baker's entry is notable given their track record of building positions ahead of clinical catalysts; RAPP is expected to report Phase 1b proof-of-concept data for RAP-219 in the first half of 2025, and Baker's timing suggests confidence in the differentiated mechanism (selective potentiation of specific GABAA subtypes to improve

Perceptive AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AAVXF2 funds BCRX2 funds CNTA2 funds CTNM2 funds CTMX2 funds IRON2 funds DYN2 funds EWTX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Perceptive Advisors Initiates $20.4M Position in Rapport Therapeutics Edelman's Perceptive Advisors—known for selective early-stage biotech picks—has initiated a meaningful 673,923-share position in RAPP, suggesting conviction in Rapport's clinical pipeline. Rapport's lead asset, RP5063, is a multimodal antipsychotic in Phase 2b for schizophrenia with differentiated mechanisms (5-HT1A agonist, D2 antagonist) designed to improve tolerability; clinical data readouts are expected in 2024-2025. This entry by a high-conviction, well-resourced investor with a track record of backing clinical winners likely reflects confidence in trial execution and upcoming data catalysts.